SCHEMBL4226282

SCHEMBL4226282

O=C(O)COCc1ccccc1.[Ag]

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.58
PAM P19021 1/20 0.52
ALDH1A1 P00352 3/20 0.50
GRM5 P41594 2/20 0.50
NPC1 O15118 2/20 0.48
RAB9A P51151 1/20 0.48
KMT2A Q03164 2/20 0.48
MAPK1 P28482 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
SLC6A2 P23975 1/20 0.48
SLC6A3 Q01959 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
ALOX15 P16050 1/20 0.48
AKR1B1 P15121 1/20 0.48
MAPT P10636 1/20 0.47
KEAP1 Q14145 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL231282 0.98 TSHR (0.61) TSHRPAMALDH1A1GRM5NPC1
Hydrochloric Acid SCHEMBL7053203 0.96 TSHR (0.58) TSHRPAMALDH1A1GRM5NPC1
Acetic Acid SCHEMBL28567289 0.90 ALDH1A1 (0.55) TSHRPAMALDH1A1GRM5NPC1
Ether SCHEMBL954914 0.88 ALDH1A1 (0.50) TSHRPAMALDH1A1GRM5NPC1
SCHEMBL8775706 0.88 TSHR (0.54) TSHRPAMALDH1A1GRM5NPC1
SCHEMBL1956559 0.88 TSHR (0.54) TSHRPAMALDH1A1GRM5KMT2A
Trifluoroacetic Acid SCHEMBL4658961 0.87 CES1 (0.52) TSHRPAMALDH1A1GRM5
SCHEMBL5041952 0.86 TSHR (0.57) TSHRNPC1RAB9A
SCHEMBL4963940 0.86 NAAA (0.53) TSHRPAMALDH1A1GRM5KMT2A
SCHEMBL4966266 0.86 NAAA (0.53) TSHRPAMALDH1A1GRM5KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572795-B2 Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-11 US disclosed
US-20090156555-A1 PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2009-06-18 US disclosed
EP-2001886-A2 PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2008-12-17 EP disclosed
WO-2007103839-A2 PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-09-13 WO disclosed
US-20070213300-A1 PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156555-A1 PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS CDK2, CDK3, CDK1 TSHR 612/4885PAM 3139/4885ALDH1A1 3301/4885
US-20070213300-A1 PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS CDK2, CDK3, CDK1 TSHR 697/4885PAM 3174/4885ALDH1A1 3055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.